Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use

被引:23
作者
Jacobson, Nora [1 ]
Horst, Julie [2 ]
Wilcox-Warren, Liam [2 ]
Toy, Alex [2 ]
Knudsen, Hannah K. [3 ]
Brown, Randy [2 ]
Haram, Eric [4 ]
Madden, Lynn [5 ]
Molfenter, Todd [2 ]
机构
[1] Univ Wisconsin, Inst Clin & Translat Res, Signe Skott Cooper Hall,701 Highland Ave, Madison, WI 53703 USA
[2] Univ Wisconsin, Ctr Hlth Enhancement Syst Studies, Madison, WI 53703 USA
[3] Univ Kentucky, Robert Straus Behav Sci Lab, Lexington, KY USA
[4] Hamm Counseling, Brunswick, ME USA
[5] Yale Sch Med, APT Fdn, New Haven, CT USA
关键词
EXTENDED-RELEASE NALTREXONE; EFFECTIVE IMPLEMENTATION; BUPRENORPHINE; ATTITUDES; METHADONE; DEPENDENCE; LEADERSHIP; ADDICTION; OVERDOSE; OUTCOMES;
D O I
10.1007/s11414-020-09706-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Medication for opioid use disorder (MOUD) is a key strategy for addressing the opioid use disorder crisis, yet gaps in MOUD provision impede this strategy's benefits. The research reported here sought to understand what distinguishes low- and high-performing organizations in building and using capacity to provide MOUD. As part of a mixed methods MOUD implementation trial, semi-structured telephone interviews were conducted with personnel from low- and high-performing MOUD-providing organizations. Seventeen individuals from 17 organizations were interviewed. Findings demonstrate the importance of individual, organization, and community-level factors in supporting the building and use of MOUD capacity. Low- and high-performing organizations showed different patterns of facilitators and barriers during the implementation process. The key difference between low- and high-performing organizations was the level of organizational functioning. A better understanding of an organization's assets and deficits at the individual, organizational, and community levels would allow decision-makers to tailor their approaches to MOUD implementation.
引用
收藏
页码:439 / 448
页数:10
相关论文
共 47 条
[1]   The Roles of System and Organizational Leadership in System-Wide Evidence-Based Intervention Sustainment: A Mixed-Method Study [J].
Aarons, Gregory A. ;
Green, Amy E. ;
Trott, Elise ;
Willging, Cathleen E. ;
Torres, Elisa M. ;
Ehrhart, Mark G. ;
Roesch, Scott C. .
ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH, 2016, 43 (06) :991-1008
[2]   Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use [J].
Alanis-Hirsch, Kelly ;
Croff, Raina ;
Ford, James H., II ;
Johnson, Kim ;
Chalk, Mady ;
Schmidt, Laura ;
McCarty, Dennis .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2016, 62 :68-73
[3]   Counselor training and attitudes toward pharmacotherapies for opioid use disorder [J].
Aletraris, Lydia ;
Edmond, Mary Bond ;
Paino, Maria ;
Fields, Dail ;
Roman, Paul M. .
SUBSTANCE ABUSE, 2016, 37 (01) :47-53
[4]   Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder [J].
Andrilla, C. Holly A. ;
Coulthard, Cynthia ;
Larson, Eric H. .
ANNALS OF FAMILY MEDICINE, 2017, 15 (04) :359-362
[5]  
[Anonymous], 2018, Opioid Crisis: Status of Public Health Emergency Authorities. GAO-18-685R Public Health Emergency for Opioid Crisis
[6]  
[Anonymous], 2017, NAT SURV SUBST AB TR
[7]  
Comer Sandra, 2015, The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use
[8]   Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions [J].
Connery, Hilary Smith .
HARVARD REVIEW OF PSYCHIATRY, 2015, 23 (02) :63-75
[9]   Understanding Attitudes Toward Use of Medication in Substance Abuse Treatment: A Multilevel Approach [J].
Fitzgerald, John ;
McCarty, Dennis .
PSYCHOLOGICAL SERVICES, 2009, 6 (01) :74-84
[10]  
Florence CS, 2016, MED CARE, V54, P901, DOI 10.1097/MLR.0000000000000625